Melanoma (previously untreated unresectable stage III or IV) - ipilimumab [ID74]: evaluation report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

 

01.  NICE’s response to comments on the Appraisal Consultation Document (ACD)

02.  Consultee comments on the ACD – Bristol Myers-Squibb

03.  Consultee comments on the ACD – OcuMel UK

04.  Consultee comments on the ACD – British Association of Dermatologists

05.  Consultee comments on the ACD -  Royal College of Physiciabns  NCRI-RCP-RCR-ACP-JCCO-Melanoma Focus

06.  Consultee comments on the ACD-  Department of Health

07. Public comments on the ACD received via the NICE website

08.  Open letter – Melanoma UK

09.  MP letter - Pauline Latham

10.  ERG review of manufacturer’s response by NHS Centre for Reviews & Dissemination and Centre for Health Economics, University of York

 

 

 

 

This page was last updated: 12 June 2014